Researchers at the University of Nottingham and neurologists at Nottingham University Hospitals NHS Trust in England will be working with a team from the Cleveland Clinic in Ohio to better understand the best therapeutic strategy for multiple sclerosis (MS) patients.
A key goal of all the projects is to improve knowledge about therapies to help doctors and MS patients choose the treatment options that best meet patients’ needs, while considering the priorities of the MS community.
In this case, the research team’s goal is to provide an answer to the question, “Does early treatment with aggressive disease-modifying therapies (DMTs) improve the prognosis for people with MS?”
The U.S. part of the trial will be headed by Daniel Ontaneda, MD, of the Mellen Center on the Cleveland Clinic Main Campus in Ohio.
The U.K. arm of the trial will be led by Nikos Evangelou, MD, associate professor of neurology and consultant neurologist, and will be conducted at eight centers across the country: Nottingham, Cardiff, Oxford, Cambridge, Plymouth, University College London, Morriston Hospital, and Royal Gwent Hospital.
The trial is expected to enroll 400 patients in the U.S. and 400 in the U.K., all with diagnosed relapsing-remitting multiple sclerosis.
“The Nottingham team is delighted to have played a role in making this study possible,” Evangelou said in a University of Nottingham news release. “This is a joint effort between neurologists, patients with MS, and MS societies in the U.K. and U.S. coming together to tackle the most important question in MS treatment – how intensive should the initial treatment of MS be?”
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?